reconstitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-26 and is reviewed periodically as new material appears.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
| Property | Value | Notes |
|---|---|---|
| Lyophilised storage | −20 °C, dry, protected from light | Vials are sealed and allowed to reach room temperature before opening |
| Reconstituted storage | 2 to 8 °C, protected from light | Short-term holding; avoid repeated freeze-thaw cycles |
| Reconstitution solvent | Water for injection or bacteriostatic water | Added slowly along the vial wall to reduce foaming and shear |
| Purity measurement | RP-HPLC with area normalisation | Acetonitrile-water gradient monitored at roughly 214 nm |
| Identity confirmation | Electrospray ionisation mass spectrometry | Observed mass compared against the calculated peptide mass |
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
With increased concerns about nuclear waste, breeding fuel cycles came under renewed interest as they can reduce actinide wastes, particularly plutonium and minor actinides such as neptunium, americium and curium. Breeder reactors are designed to fission the actinide wastes as fuel and thus convert them to more fission products. For unreprocessed uranium-oxide spent nuclear fuel, Bodansky's 2006 review described a rapid initial decrease in radioactivity as short-lived fission products decay, followed by a more gradual decrease as actinides decay. Today's commercial light-water reactors do breed some new fissile material, mostly in the form of plutonium. Because commercial reactors were never designed as breeders, they do not convert enough uranium-238 into plutonium to replace the uranium-235 consumed. Nonetheless, at least one-third of the power produced by commercial nuclear reactors comes from fission of plutonium generated within the fuel. Even with this level of plutonium consumption, light water reactors consume only part of the plutonium and minor actinides they produce, and nonfissile isotopes of plutonium build up, along with significant quantities of other minor actinides. Since breeder reactors on a closed fuel cycle would use nearly all of the isotopes of these actinides fed into them as fuel, their fuel requirements would be reduced by a factor of about 100. Waste volume alone does not determine disposal requirements. A 2023 DOE assessment identified radionuclide inventory, heat output, chemical and physical properties, and packaging as relevant factors.
=== In Vietnam === The clinical trials of the vaccine in Vietnam are completely sponsored and funded by Vinbiocare, a Vingroup subsidiary. On 2 August, Vinbiocare received regulatory approval to start a clinical trial of its COVID-19 vaccine candidate in Vietnam. The company will coordinate with the Ministry of Health to carry out Phase I-III clinical trials of VBC-COV19-154 vaccine on 21,000 adults in three phases in August 2021. The clinical trial Phase 1 will recruit 100 volunteers to evaluate the safety, tolerability, and initial assessment of immunogenicity of the vaccine. The clinical trial Phase 2 enrolled 300 volunteers at designated medical facilities in multiple provinces, while the third phase of human trials is expected to involve 20,600 volunteers, including phase 3a (600 volunteers) and 3b (20,000 volunteers). Those receiving placebo will receive active vaccine after 6 months, while all participants will be followed up for 1 year. In December 2021, the company plans to complete and submit procedures to the Ministry of Health, applying for an emergency authorization in Vietnam.
== Impact on protein function == Missense mutation refers to a change in one amino acid in a protein arising from a point mutation in a single nucleotide. Amino acids are the building blocks of proteins. Missense mutations are a type of nonsynonymous substitution in a DNA sequence. Two other types of nonsynonymous substitutions are nonsense mutations, in which a codon is changed to a premature stop codon that results in the resulting protein being cut short, and nonstop mutations, in which a stop codon deletion results in a longer but nonfunctional protein. The latter two types are not considered to be missense mutations.
=== Development of the concept === In 1893, the American botanist Charles Reid Barnes proposed two terms, photosyntax and photosynthesis, for the biological process of synthesis of complex carbon compounds out of carbonic acid, in the presence of chlorophyll, under the influence of light. The term photosynthesis is derived from the Greek phōs (φῶς, 'gleam') and sýnthesis (σύνθεσις, 'arranging together'), while photosyntax comes from sýntaxis (σύνταξις, 'configuration'). Over time, the term photosynthesis came into common usage. Later discovery of anoxygenic photosynthetic bacteria and photophosphorylation necessitated redefinition of the term.
Corticotropic releasing hormone (CRH): stimulates ACTH secretion Thyrotropin releasing hormone (TRH): stimulates TSH and prolactin secretion Growth hormone releasing hormone (GHRH): stimulates GH secretion Somatostatin: inhibits GH (and other hormone) secretion Gonadotropin releasing hormone (GnRH): stimulates FSH and LH secretion Prolactin releasing hormone (PRH): stimulates PRL secretion Prolactin inhibiting hormone (dopamine): inhibits PRL secretion These hypothalamic hormones are secreted in pulses. They act on specific membrane receptors. They are also glycoproteins. They stimulate:
Sources: en.wikipedia.org
A drug-related wider conflict broke out in 2024. In 2012, the US sent DEA agents to Honduras to assist security forces in counter-narcotic operations. Honduras has been a major stop for drug traffickers, who use small planes and landing strips hidden throughout the country to transport drugs. The DEA, working with other US agencies such as the State Department, the CBP, and Joint Task Force-Bravo, assisted Honduran troops in conducting raids on traffickers' sites of operation.
== Applications == Targeted analysis allows the thorough analysis of all ions, at all abundance range above the noise level, at any time window in the experiment. In contrast, non-targeted analysis would, typically, only allow detection of the most abundant 50-100 ions over the entire experiment time. Such limitation of non-targeted analysis makes it less suitable for analyzing highly complex, highly dynamic sample such as human blood serum. However, the methods of utilizing targeted mass spectrometry are still at a primitive stage, in the sense that the inclusion list used in the targeted analysis is typically manually typed-in by scientists. In addition to that, only one inclusion list is allowed for the entire experiment. Such manual process is both labor-intensive and error-prone. This is largely due to the lack of software to control the mass spectrometer.
== Early life == Born to an Indian Air Force officer, he accompanied his parents with their postings at various Indian cities. As a consequence, his education was cross cultural and spread across various regions in India and the schools he studied in include Frank Anthony School in Agra, Bishops School in Pune, Jesus and Mary School in Amritsar before completing his high schooling from The Air Force School in New Delhi. He subsequently completed his professional education from LBS College of Advanced Maritime Studies and Research as a certified Master Mariner, having earlier completed his professional training at the TS Rajendra.
==== July 2021 settlement ==== Four major drug manufacturers and distributors, J&J, McKesson, Cardinal Health, and AmerisourceBergen, have agreed to a settlement announced by a group of state attorneys general in July 2021. The settlement, $26 billion (US), will be used on the prevention of opioid addiction and treatment programs. J&J will pay $5 billion (US) over the next five years; the remaining $21 billion (US) will be paid by the other firms. The settlement, when approved by a "significant" group of states and local governments, will settle more than 4,000 individual legal actions. All four of the manufacturing firms disputed all allegations in the lawsuits.
The prevalence of MS shows a geographic gradient: it is more common in people who live farther from the equator (e.g., those who live in northern regions of the world). Exceptions include ethnic groups that are at low risk and that live far from the equator, such as the Sami, Amerindians, Canadian Hutterites, New Zealand Māori, and Canada's Inuit, as well as groups that have a relatively high risk and that live closer to the equator such as Sardinians, inland Sicilians, Palestinians, and Parsi. The geographical gradient can, at least in part, be explained by exposure to sunlight and resulting vitamin D levels. Vitamin D plays various roles in the immune system, including helping the body get rid of pathogens and regulating immune tolerance. Low vitamin D levels are a risk factor for developing MS and for disease progression beyond the first attack. Sunlight exposure may reduce risk independently from vitamin D. While there are dietary sources of vitamin D (e.g. fatty fish and some mushrooms), this usually is not enough to meet the body's need. The risk of MS tracks the sunlight exposure in childhood.
Sources: en.wikipedia.org
== Method == Generally, negative ions are created (atoms are ionized) in an ion source. In fortunate cases, this already allows the suppression of an unwanted isobar, which does not form negative ions (as 14N in the case of 14C measurements). The pre-accelerated ions are usually separated by a first mass spectrometer of sector-field type and enter an electrostatic "tandem accelerator". This is a large nuclear particle accelerator based on the principle of a tandem van de Graaff accelerator operating at 0.2 to many million volts with two stages operating in tandem to accelerate the particles. At the connecting point between the two stages, the ions change charge from negative to positive by passing through a thin layer of matter ("stripping", either gas or a thin carbon foil). Molecules will break apart in this stripping stage. The complete suppression of molecular isobars (e.g. 13CH− in the case of 14C measurements) is one reason for the exceptional abundance sensitivity of AMS. Additionally, the impact strips off several of the ion's electrons, converting it into a positively charged ion. In the second half of the accelerator, the now positively charged ion is accelerated away from the highly positive centre of the electrostatic accelerator which previously attracted the negative ion. When the ions leave the accelerator they are positively charged and are moving at several percent of the speed of light. In the second stage of mass spectrometer, the fragments from the molecules are separated from the ions of interest.
There are various competing calculation methods for the drug accumulation ratio, yielding somewhat different results. A commonly used formula defines Rac as the ratio of the area under the curve (AUC) during a single dosing interval under steady state conditions to the AUC during a dosing interval after one single dose:
Arsenic trioxideα Asparaginaseα Bendamustineα Bleomycinα Calcium folinate (leucovorin calcium)α Capecitabineα Carboplatinα Chlorambucilα Cisplatinα Cyclophosphamideα Cytarabineα Dacarbazineα Dactinomycinα Daunorubicinα Docetaxelα Doxorubicinα Doxorubicin (as pegylated liposomal)α Etoposideα Fludarabineα Fluorouracilα Gemcitabineα Hydroxycarbamide (hydroxyurea)α Ifosfamideα Irinotecanα Melphalanα Mercaptopurineα Methotrexateα Oxaliplatinα Paclitaxelα Pegaspargaseα Procarbazineα Realgar Indigo naturalis formulationα Tioguanineα Vinblastineα Vincristineα Vinorelbineα
==== Hydrodynamic countercurrent chromatography (CCC) ==== The operating principle of CCC instrument requires a column consisting of an open tube coiled around a bobbin. The bobbin is rotated in a double-axis gyratory motion (a cardioid), which causes a variable gravity (G) field to act on the column during each rotation. This motion causes the column to see one partitioning step per revolution and components of the sample separate in the column due to their partitioning coefficient between the two immiscible liquid phases used. There are many types of CCC available today. These include HSCCC (High Speed CCC) and HPCCC (High Performance CCC). HPCCC is the latest and best-performing version of the instrumentation available currently.
Sources: en.wikipedia.org
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.
Liquid chromatography coupled to mass spectrometry is the most common approach because it combines a retention time with a mass measurement. A chromatographic peak alone cannot establish which peptide is present, so mass determination or amino acid analysis is used as an orthogonal confirmation alongside the separation.
This depends on buffer, pH, and concentration, and published stability data for this peptide are limited. In practice laboratories work through a refrigerated solution within a few weeks and discard samples that show cloudiness or visible particles. Freezing and thawing repeatedly is generally discouraged.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.